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1 Executive Summary 
1.1 Aim 
In 2010 NICE released a clinical guideline recommending that natriuretic peptide (NP) testing in 
patients with suspected heart failure without previous myocardial infarction can accelerate 
diagnosis of heart failure and also avoid unnecessary echocardiography. A framework for the 
evaluation of the value of implementation activities is applied to this recommendation for NP 
testing. 
 
1.2 Methods  
The following quantities were estimated: expected value of perfect implementation (the maximum 
the NHS can invest on implementation activities whilst still accruing some positive value from the 
intervention); expected value of actual implementation (the maximum the NHS can invest on 
implementation activities for specific increases in utilisation); and value of the implementation 
activity (the additional value of the specific implementation activity given its expected costs and 
effectiveness).  
Data sources used to inform the model included: published data on disease incidence; cost-
effectiveness data from a published Health Technology Assessment (HTA) which informed the 
clinical guidelines; cost and effectiveness evidence from an intervention designed to increase NP 
utilisation in London; data on utilisation and disease incidence from a clinical expert; audit data on 
NP testing utilisation; and a systematic review of implementation initiatives. Diffusion curves were 
estimated based on historic data to produce predictions of future utilisation. Incremental costs and 
quality-adjusted life years (QALYs) of N testing compared to ‘do nothing’ were estimated to be -
£3.88 and 0.08 respectively. The annual suspected Heart Failure (HF) population in England and 
Wales was estimated to be 210,000. Current utilisation and optimal maximum utilisation of NP 
testing were estimated to be 4.4 and 8.6 per 1,000 population respectively. The implementation 
intervention was estimated to cost approximately £24K and assumed to result in an absolute 
increase in utilisation of 5%. Both a static population analysis and multi-period analysis were 
undertaken and results are presented for cost-effectiveness thresholds of £20,000 and £30,000 per 
QALY gained. 
  
1.3 Results 
There appeared to be considerable value in additional implementation efforts directed towards 
encouraging the utilisation of NP testing for persons with suspected HF. At a threshold of £20,000 
per QALY gained, additional investment in an activity that increases utilisation by 5% (absolute 
increase in utilisation rates) would generate an additional 799 QALYs (£16 million in terms of 
monetary equivalent) across England and Wales, compared to the use of these resources in other 
(health generating) National Health Service (NHS) activities. Scenario analyses demonstrated that 
value to the NHS was sensitive to uncertain model inputs such as the size of the eligible population 
and the efficacy of the implementation intervention. The analysis highlighted a lack of evidence on: 
cost effectiveness, effectiveness of implementation intervention, utilisation, and population size. 
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1.4 Conclusions 
This framework can be applied to any existing cost effectiveness analysis, thus helping a decision 
maker to quantify the value of investing resources into increasing utilisation in a manner consistent 
with the value assessment of new interventions conducted by the National Institute for Health and 
Care Excellence (NICE). This case study provides a useful demonstration of the practical challenges 
faced in populating such a model. In particular, the importance of publishing incremental costs and 
QALYs related to clinical guidelines compared to current care is highlighted. Data on diffusion of 
utilisation is crucial for such evaluations. 
 
2 Background 
2.1 Diagnosing heart failure 
The prevalence of heart failure (HF) is expected to rise in the future as a result of an ageing 
population, obesity, improved survival of people with ischaemic heart disease and more effective 
treatments for heart failure. Hospital episode statistics (HES) data show that the number of episodes 
with primary diagnosis of HF increased from 117,000 in 2010/2011 to 127,000 in 2012/2013; an 
increase of 4.2% per annum.1 
B-type natriuretic peptides (B-type natriuretic peptide (BNP) or N-terminal pro-B type natriuretic 
peptide (NTproBNP)) referred to as NPs, are markers of heart failure. The NICE clinical guideline 108 
(CG108) released in 2010 recommends that testing for NPs in patients with suspected heart failure 
without previous myocardial infarction (MI) can accelerate diagnosis of heart failure and also avoid 
unnecessary echocardiography. Figure 2.1 shows the HF pathway described in CG108.2  If NP testing 
shows high levels (BNP>400pg/ml or NTproBNP>2000pg/ml) then the patient is referred directly to 
specialist assessment and echocardiogram within 2 weeks. If NP testing shows raised levels (BNP 
100-400pg/ml or NTproBNP 400-2000pg/ml) then the patient is referred to specialist assessment 
and echocardiogram within 6 weeks. If NP testing shows normal levels (BNP<100pg/ml or 
NTproBNP<400pg/ml) heart failure is unlikely. For trusts which are not yet utilising NP testing in line 
with CG108, a NP test and/or Electrocardiography (ECG) are used to rule out HF in all patients 
regardless of MI history. This pathway is shown in Figure 2.1. 
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Figure 2.1A: Heart Failure Pathway described in NICE clinical guideline 108
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Figure 2.1B: Diagnostic pathway of trusts not yet utilising NP testing in line with CG108
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2.2 Barriers to consistent adoption of BNP testing in diagnosing chronic heart failure 
In general terms utilisation can be increased via the following three routes: (1) Increasing the 
number of trusts who offer BNP testing, (2) Increasing the number of General Practitioners (GPs) 
who refer for BNP testing, (3) Increasing the number of patients who agree to undertake BNP 
testing.  Although in general patients’ acceptability of the intervention needs to be maximised, this is 
not relevant in the case of BNP testing. This report focuses increasing utilisation by addressing 
barriers to the adoption of NP testing by trusts. 
The NICE implementation collaborative (NIC) identified the following barriers to adoption of NP 
testing: 
 Cost impact uncertainties. While savings will be made via the reduction in echocardiograms, 
funding for the tests will be required by the NHS pathology departments 
 Long term savings are often not prioritised over ‘in year’ spend. It can be difficult to get 
commissioners and providers to see the value of a diagnostic which can create long term 
savings 
 Complexity of (partial) decommissioning of services within the NHS 
 Failure to communicate heart failure strategy throughout the NHS 
 Complexities involved in redesigning patient pathways to accommodate this technology. 
 
3 Conceptual framework for valuing implementation initiatives  
 
This case study applies the framework for valuing implementation initiatives described in “Getting 
cost-effective technologies into practice: the value of implementation- Draft report on framework 
for valuing implementation initiatives”.5 
The framework assesses the value to the NHS of investing in implementation activities to increase 
utilisation of interventions recommended by NICE. The expected value of perfect implementation 
represents the maximum the NHS can invest on implementation activities whilst still accruing some 
positive value from the intervention. The expected value of actual implementation represents the 
maximum the NHS can invest on implementation activities for specific increases in utilisation (i.e. for 
a specified % increase). All things equal, the expected value of actual implementation is larger for 
interventions with more favourable cost-effectiveness estimates (i.e. the degree of cost-
effectiveness is potentially important), with larger patient populations and lower utilisation of the 
intervention (both in terms of existing levels of utilisation and/or low anticipated future uptake). The 
value of the implementation activity represents the additional value of the specific implementation 
activity given its expected costs and effectiveness. The value of the implementation activity is larger 
the smaller the costs and the larger the increase in utilisation (effectiveness). 
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4 Methods 
4.1 Net benefit. Is the technology of value to the NHS? 
The value of NP testing corresponds to the lifetime net benefit from using NP testing for the 
diagnosis heart failure, as described in NICE CG108, for the average patient presenting with 
suspected heart failure. The economics of the diagnostic section of the NICE CG108 was informed by 
the HTA report by Mant et al 2009.6 (Note that the economic model in Appendix H of CG108 only 
relates to the treatment section of the guideline). 
4.1.1 Cost-effectiveness analysis by Mant et al. 
The HTA undertakes decision analysis to test the impact of plausible diagnostic strategies for the 
diagnosis of heart failure in primary care on costs and diagnostic yield in the UK setting. It 
determines cut-points (or diagnostic thresholds) for NP testing considering the costs of echo and the 
costs of missed diagnoses. The study established how much a diagnosed case of heart failure is 
worth, the willingness to pay (WTP). From the WTP, the study calculated the diagnostic threshold for 
NP testing which varies according to the pre-test probability (prevalence of heart failure, depends on 
MICE score) and diagnostic performance of NP testing. NP thresholds were calculated assuming that 
the cost-effective NP threshold is that at which the cost of echo matches the WTP. 
Three alternatives were considered in the decision analysis: do nothing, perform NP test then echo 
depending on the result of NP, and perform echo for all. Patient groups were defined according to 
MICE (Male gender, history of myocardial Infarction, basal Crepitations, oEdema) score. The MICE 
rule allocates the following points: (male: 2 points, history of myocardial infarction: 6 points, 
crepitations: 5 points, ankle oedema: 3 points).7 The base-case analysis only considers the costs to 
the NHS: costs of the tests, costs of hospitalisations avoided and costs of medication. Subsequent 
analyses include QALY gains from treatment following earlier diagnosis. 
The WTP to diagnose one case of heart failure was estimated. The incremental cost-effectiveness 
ratios (ICERs) calculated related to additional cost per additional case detected and these were 
compared to the WTP thresholds. The survival benefit from early treatment vs late treatment (6 
months later) was estimated using data from the Framingham study. Assuming that patients’ EQ-5D 
throughout is 0.65, the overall QALY gain is 0.106 at 3 years, 0.161 at 5 years and 0.254 at 10 years’ 
time horizon. The cost to the NHS of avoided hospitalisations less the cost of additional drug costs 
from early diagnosis is £270. 
 
4.1.2 Estimates of cost effectiveness used in this study 
There are several key differences between the economic analyses undertaken by Mant et al and the 
clinical guidelines. 
 Mant et al suggest that a person’s diagnostic pathway be determined by their MICE score 
and the cost-effectiveness of different diagnostic strategies are calculated for each MICE 
score. The NICE CG108 suggests different diagnostic pathways determined by whether the 
person has a history of MI. 
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 The Mant et al study applies different NP test thresholds for referral to echocardiography 
dependent on a person’s MICE score. The NICE CG108 recommends a threshold of 
BNP>400pg/ml or NTproBNP>2000pg/ml for 2 week referral and BNP>400pg/ml or 
NTproBNP>2000pg/ml for 6 week referral to echocardiography. 
 The Mant et al study compares a strategy of NP testing to ‘do nothing’ in which no further 
investigations are made. The 2003 NICE guidelines recommend that persons with suspected 
HF receive an ECG and/or NP test (where available). Hence it is suggested that ECG 
represents current care (where NP testing is not available) and that this should be the 
comparator. The study by Mant et al did include information on the effectiveness of ECG but 
ECG was not included as a comparator within the economic section.  “Electrocardiography 
(ECG), B-type natriuretic peptides (BNP) and N-terminal pro- B-type natriuretic peptides (NT-
proBNP) all had high sensitivities (89%, 93% and 93% respectively). Chest X-ray was 
moderately specific (76–83%) but insensitive (67–68%). BNP was more accurate than ECG, 
with a relative diagnostic odds ratio of ECG/BNP of 0.32 (95% CI 0.12–0.87).”6 
For the purposes of this project the model and results from the Mant et al HTA was adapted to more 
closely represent the CG108. A diagnostic strategy dependent on previous MI is modelled with a NP 
testing threshold for referral of BNP>400pg/ml or NTproBNP>2000pg/ml, applied as in the NICE 
CG108. However, the comparator for this analysis remains ‘do nothing’ as data on the cost-
effectiveness of ECG were not provided within the HTA, nor were available from the HTA authors. 
The value of incremental costs and QALYs compared to a comparator of ECG are likely to be 
considerably lower than for the comparator ‘do nothing’. Estimates of the sensitivity and specificity 
of the BNP test were obtained from one of the HTA authors.8 Table 4.1 presents a summary of this 
adaptation of the Mant et al HTA. 
Table 4.1: Adaptation of economic analyses from Mant et al HTA
 
 
 
 
 
 
4.2 Current value. What is the value of the technology given current utilisation and 
population size? 
Economic Analyses for CG108 based on data from Mant et al HTA
Rule: If previous MI then echo;  If no previous MI then BNP test, echo if BNP >100 in line with CG108
Cost echo 87£                NICE costing template
Cost BNP 28£                NICE costing template
Savings form reduced admissions less drug costs270£            Mant et al
QALY gain (10 year time horizon) 0.254 Mant et al
No previous MI 0.86              PC from Andrea Roalfe 14 April 2014
Pre-BNP probability of HF, No MI 0.29              PC from Andrea Roalfe 14 April 2014
Sensitivity 0.83              PC from Andrea Roalfe 14 April 2014
Specificity 0.67              PC from Andrea Roalfe 14 April 2014
BNP positivity 0.48              Calculated from above
Previous MI 0.14              Calculated from above
Probability of HF, previous MI 0.67              PC from Andrea Roalfe 14 April 2014
Additional cases 301 Calculated from above
For 1,000 persons with suspected HF
Cost (CG108 versus nothing) 3,881-£          Calculated from above
QALYs (CG108 versus nothing) 76.40            Calculated from above
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4.2.1 Population size 
The population eligible for NP testing consists of persons presenting with suspected heart failure. 
The scope of this study is to produce predictions for England and Wales. 
Estimates of the incidence of heart failure vary considerably between sources: 
 An estimate of the annual incidence of heart failure based on General Practise Research 
Database (GPRD) data is 22,542 cases for England and Wales.9 
 The Hillingdon Heart Failure Study used a combination of clinical assessment, 
echocardiography and radiography to diagnose heart failure in the study population and 
adhered to European Society of Cardiology guidelines for its deﬁnition of heart failure. The 
study found a crude incidence rate of 140/120 per 100,000 for men/women and estimated 
59,000 cases annually in England and Wales.10 
 A significant proportion of total incidence will present via a HF clinic and the remainder will 
be admitted to hospital. For Sheffield heart failure clinic an incidence of 98 per 100,000 was 
seen.11 This is equivalent to 55,000 cases annually in England and Wales. We note that the 
Sheffield HF diagnostic clinic data was restricted to the patients well enough to attend the 
clinic and did not include patients who were admitted to hospital with acute heart failure 
during this period. 
 A clinical expert estimates an annual incidence of 70,000 new cases in England and Wales. 
 Data from Hospital Episode Statistics gives 121,000 inpatient episodes for heart failure per 
year in England and Wales.12  Clinical opinion suggests that 20-35% of such episodes are 
new, indicating an annual incidence of 23,000-40,000 cases.11 
Based on these data sources we will assume that the annual incidence of HF in England and Wales is 
70,000 in the base case and 50,000 will be considered in a scenario analysis. Based on the Cowie et 
al study the prevalence of HF in persons presenting with suspected HF is 33%. Hence the population 
of persons presenting with suspected HF is of size 210,000 for the base case (3.7 per 1,000 
population) and 150,000 in the scenario analysis. 
 
4.2.2 Current utilisation of NP testing  
Data on the current utilisation of NP testing was available from two sources: the NHS Atlas of 
variation in diagnostic services, and from an audit developed by the Healthcare scientists’ innovation 
project. 
NHS Atlas of variation in diagnostic services 
The NHS Atlas of variation in diagnostic services was published in November 2013.13 It provides data 
on the estimated annual rate of use for NP tests ordered by GPs per 1,000 practice population, by 
primary care trust (PCT), 2012.  The data is a sample (23 days in June 2012) and has been gathered 
from the live e‐Reporting Pathology Messaging Implementation Programme (PMIP) feed as part of 
an audit of the data quality within the messages. The data indicates wide variation in test usage 
possibly due to differences in clinical practice or variations in test availability, either because of local 
laboratory policy or funding restrictions. Data was available from 111 out of 151 PCTs (74%). The 
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average estimated annual rate was 4.43 per 1,000 weighted population (95 percentiles 0.10-11.38). 
However, as the GP testing information is based on a sample set only and reflects only 23 days of 
extraction from the PMIP system, the estimates should be used with caution. 
The NHS Atlas of variation in diagnostic services also provides data on the rate of echocardiography 
activity per 1,000 weighted population, by PCT, 2012/13. Data quality and completeness of activity 
data should be good. However, given that data are only collected at an aggregate level (i.e. total 
counts by PCT/provider), it is not possible to do detailed standardisation to remove the effect of 
different population compositions. The average estimated annual rate was 21 per 1,000 practice 
population (95 percentiles 9-33). 
Table 4.2: NP and echocardiography activity by PCT from the NHS atlas of variation in 
diagnostic services 
  
 
Healthcare scientists’ innovation project  
The Healthcare Scientists innovation project developed an audit flowchart process ‘Pipeline 
adoption scale’ which describes 22 steps associated with the adoption of a new technology.14  A total 
of 14 of these 22 steps were found to be completed by NHS healthcare scientists. A questionnaire 
was developed to use to undertake an audit of NTproBNP testing, see Figure 4.2A. 
 
 
 
 
 
 
 
 
 
 BNP tests ordered by GPs  Echocardiography activity 
PCTs with available data 74% 100%
Mean 1534 7289
Min 14                                                          212                                                           
Max 6,114                                                    47,370                                                     
Percentiles (29 - 4,342) (1,927 - 17,810)
per 1,000 practice population per 1,000 weighted population
Mean 4.4 21.0
Min 0.0                                                         1.2
Max 14.4                                                       42.0
Percentiles (0.10 - 11.38) (9 - 33)
Mean 248,565                                                1,179,336                                               
Min 2,692                                                    68,413                                                     
Max 805,699                                                2,356,309                                               
Percentiles (5,495 - 638,074) (477,346 - 1,849,523)
Estimated annual tests for PCT population
per population of England and Wales
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Figure 4.2A: Questions included within the audit. 
 
In December 2012, the 26 provider trusts in London were audited to determine which stage along 
the implementation pipeline they were at. A response was received from 24 trusts within a 2 week 
period. 20 Trusts were included in the study providing data on the number of NTproBNP tests 
completed in the previous 6 month period (late 2012). This data has been converted to an estimated 
annual number. Figure 4.2B shows that the majority of provider trusts were in the early stages of 
implementation of NP testing with less than 100 tests being performed annually. 
Figure 4.2B: Estimated annual NTproBNP tests from audit of 26 London Provider trusts
 
A national audit (excluding London) was undertaken in October 2013. A total of 47 trusts responded 
to the questionnaire. Details of the questionnaire are shown in Figure 4.2C. The questionnaire 
showed that 43/47 (91%) of the trusts offer BNP testing. BNP testing appears to be offered 
universally in London the North East and much of the North. 
Questions
1 Does your trust offer BNP testing?
2a Would your trust consider offeringBNP testing?
3a What barriers are preventing successful adoption?
3b State reason for this
3c Where are you in introducing BNP testing?
2b Does your trust actively use BNP testing?
3d Are you in the post adoption phase for BNP?
4a Is BNP analysis performed in primary care as a POCT service?
4b Where are you in introducing BNP testing?
3e State the number of BNP tests performed?
4c State number of referrals following BNP testing?
5a State the number of echos following BNP testing?
6a
If applicable state what other organisations your Trust performs BNP 
testing for eg PCTs/GP surgeries. Account for this in Qu 3e answer.
7a Are there other areas you could roll out to?
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Figure 4.2C: Estimated annual BNP test from national audit (excluding London) 
 
The data from the London audit and the national (excluding London) audit are at provider hospital 
level. Each provider hospital may receive patients from more the one PCT (particularly if they are 
located near a PCT boundary); it is therefore not possible to have data on the population size served 
by each provider. This means that it is not possible to compare the estimates of BNP test usage 
between providers, as they serve populations of different and unknown sizes.  
BNP utilisation estimates 
As provider population sizes were not available, BNP testing rates could not be obtained from the 
audit data and the data cannot be compared to the data from the Atlas of variation in diagnostic 
services. Hence, data from the Atlas of variation in diagnostic services was used to inform BNP 
current utilisation estimates.  
The estimates of population size suggest that the maximum annual number of tests should be 
210,000 or 3.7 per 1,000 patient population. This estimate is not compatible with the data from the 
diagnostics Atlas. As there is considerable uncertainty surrounding the number of persons with 
suspected heart failure presenting for each one person with actual heart failure, the diagnostics atlas 
data will be used to estimate maximum utilisation. 
We make the assumption that some PCTs within the diagnostics Atlas data set will have achieved 
maximum optimal utilisation. Maximum utilisation was 14.4 BNP tests per 1,000 practice population 
but this rate was only observed for one PCT. Clinical opinion suggests that additional NP testing is 
also undertaken, which is not in-line with CG108. This includes: GP's using NP as a screening test in 
the absence of symptoms, GPs using the test as a way to find access to cardiology opinion, and doing 
multiple tests on the same patient.11 Hence, we suggest that the optimal maximum utilisation will be 
lower than the observed maximum rate of 14.4 tests per 1,000 population. 
Examining the percentiles of the data shows that 10% of PCTs within the data set had a BNP 
utilisation rate of over 8.6 tests per 1,000 patient population and 20% a rate of over 7.1 tests per 
1,000 patient population. Using 8.6 as maximum utilisation rate for base case analysis and 7.1 for 
scenario analysis, we see that current utilisation is at 51% (base case) or 63% scenario analysis) of 
maximum utilisation. 
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4.3 Expected value of perfect implementation. What is the value of increasing 
utilisation so all eligible patients receive the test? 
4.3.1 Diffusion curves for utilisation of NP testing 
Diffusion theory suggests an S-shaped curve is appropriate to represent the total cumulative 
utilisation over a period of time.15 This entails an exponential growth in early periods that levels off 
and declines later. However, it is difficult to know whether the utilisation of NP testing follows this 
pattern and, if so, in what stage of the curve is utilisation currently at. In addition diffusion models 
will be affected by the following: technology characteristics such as usability, benefit-risk profile and 
price; characteristics of the organisation; external environment; characteristics of the individual 
adopters, such as skills, motivation, acceptance and beliefs; available evidence; available resources. 
The diffusion curve will be informed by the date which NP testing started to be used as a means of 
‘rule-out’ for echocardiography. Section 4 of the NHS Improvement report indicates that several 
trusts undertook pilots and audits of NP testing in the period 2005-2007.16 The NHS Improvement NP 
resource was published in 2008. The NICE CG108 and the NICE guidance costing template were 
released in August 2010. The NHS technology adoption centre (NTAC) adoption pack was produced 
in 2013. 
A S shaped curve (of the form f(t)=1/(1_exp(-at+k))) was fitted to two data points for 2010 and 2012. 
Utilisation in 2012 was based on estimates from the Diagnostics Atlas data as described in a previous 
section. In the NICE costing template expert clinical opinion estimated that without the NICE CG108 
approximately 30% of patients currently receive a BNP or NTproBNP test and approximately 90% 
currently receive an ECG.4 These estimates reflect the situation in 2010. In the base case we assume 
that for these 30% utilisation was 50% of optimal maximum utilisation i.e. 15%. These diffusion 
curves are presented in Figure 4.3. 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: BNP utilisation diffusion curves 
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4.4 Expected value of actual implementation. What is the value of increasing 
utilisation from current to achievable? 
Utilisation may increase with implementation activities; however, it may not reach full (or perfect) 
implementation. The effectiveness of implementation activities is likely to vary with the type of 
activity and its particular context. 
4.4.1 Initiatives to increase implementation 
The NIC have identified the following list of initiatives which could increase the implementation of 
CG108: 
 Ensure that a known individual is accountable for the implementation of CG108 in each 
Clinical Commissioning Group 
 Ensure that that individual is trained and aware of the business economics and patient 
outcome benefits of early diagnosis of heart failure enabled by CG108 
 Develop a template communication package targeted at general practitioners, for use by 
clinical commissioning group (CCG) accountable individual 
 Define a reporting mechanism to enable CCG to track usage in individual practitioners 
 Input to discussion of ‘aligning financial incentives’ to reward adoption 
4.4.2 Resources designed to increase implementation 
In November of 2010, the Innovative Technology Adoption Procurement Programme (iTAPP) was 
launched. This programme encourages NHS-wide adoption of high impact innovative medical 
technologies that can increase the quality of care provided to patients, whilst reducing the overall 
cost of care. Medical technology companies are invited to submit details of specific medical 
technologies that would fall under the remit of iTAPP.  iTAPP is now being transitioned to the 
National Institute for Health and Clinical Excellence. An adoption pack is available for NP testing on 
the NTAC website.17 This is useful, though it is poorly advertised so usage may be low.  
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NHS Improvement (now NHS Improving Quality (NHSIQ)) produced a resource ‘Heart Improvement 
Programme: Brain-type Natriuretic Peptide (BNP): An Information Resource for Cardiac Networks’ in 
2008.16 They also produced a tool for trusts to use to estimate the cost effectiveness of NP testing 
for their population, but there were insufficient funds to further develop this tool. 
The ‘Implementing NICE guidance costing template’ which aims to help organisations in England, 
Wales and Northern Ireland plan for the financial implication of implementing the NICE clinical 
guideline on chronic heart failure. It produces estimates of the cost impact based on assumptions 
made about current practice and a prediction of how current practice may change following 
implementation. 
4.4.3 NHS London NP testing implementation initiative 
Description of NHS London NTproBNP testing implementation initiative 
The first part of the initiative involved determining the barriers to implementation and the 
developing the pipeline adoption scale. This was organised by a project manager (Stefanie Radford) 
with input from one other (Fiona Carragher) and a small group of scientists. 
An audit was undertaken in which 26 London provider trusts were asked to complete a question 
regarding their use of NTproBNP testing. ‘Intervention trusts’ were allocated on the basis of 
delivering the lowest numbers or no NTproBNP tests. The Intervention trusts were supported in a 
variety of ways including: peer support from London Scientific & Diagnostic Network, help with 
leadership, and commissioning problems. Activities includes: sharing resources and/or template 
documentation, networking and engagement among key stakeholders including 
manufacturers/suppliers. A two hour workshop was attended by 5 exemplar trusts and 3 
Intervention trusts in February 2013. One or two persons from each trust attended. Knowledge, 
business plans and contact details were shared. The workshop may have led to trusts undertaking 
initiatives to allow implementation such as training.14;18 
Effectiveness of the NP London implementation initiative 
The 5 intervention trusts and 10 control trusts were re-engaged in November 2013 to obtain data 
on: (1) change in number of NTproBNP tests undertaken, and (2) movement along pipeline adoption 
scale (if appropriate). Data was available from 2 of the 5 intervention trusts and 3 of 10 control 
trusts. We note that implementation rates may vary between trusts for other reasons: resources, 
trained staff, and availability of echo facilities, use of NICE guidelines. 
For the control trusts increases in NTproBNP testing of 19% and 35% were observed in 2 trusts in the 
12 month period January 2013 to December 2013. The third control trust did not provide NTproBNP 
test figures but stated that they were still offering the same service. 
For the interventions trusts, 1 provider trust went from not being on the pipeline adoption scale to 
the ‘adoption’ phase at step 10 on the pipeline adoption scale (sign off of business case). 1 provider 
trust remained at step 5 (only offer to inpatients, currently working on business case). 
Cost of NP pro BNP London implementation initiative  
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An estimate of the cost of the workshop was developed by EEPRU and validated by S Radford. The 
estimate includes costs for staff time and consumables costs based on information from the 
workshop organiser.18 It was assumed that the top and bottom 20% of trusts would be invited to the 
workshop. (With the top 20% acting as exemplar trusts and the bottom 20% intervention trusts). 
This corresponds with the uptake observed in the 20 London trusts who responded in the LSDN 
project. It was assumed that two members of staff from each trust would be invited in addition to 
three other experts. It was assumed that the workshop would be arranged and facilitated by a 
project manager. Unit costs for staff time were taken from the personal social services research unit 
costs of health and social care 2013.19 The total cost was estimated to be £4,172 and Table 4.4A 
provides a breakdown of this cost.  
Table 4.4A: Cost of London BNP Implementation Intervention
 
 
4.4.4 Implementation initiatives identified from the systematic review 
Utilisation may increase with implementation activities; however, it may not reach full (or perfect) 
implementation. The effectiveness of implementation activities is likely to vary with the type of 
activity and its particular context. A systematic review was conducted to establish the effectiveness 
of implementation activities.20 This review included 27 systematic reviews examining the 
effectiveness of activities to improve the implementation of guidelines. The following types of 
initiative are included.  
Table 4.4B: Type of implementation initiatives included within the systematic review
 
Cost of intervention
Workshop organisation and facilitation time (days) 2
Workshop consumables costs £500
Hospital radiographer (per hour) £34
Workshop participants time (hours) 4
Number of trusts invited to workshop (per 25 trusts) 10
Number of workshop participants (per 25 trusts) 23
Workshop participants time cost £3,128
Workshop organisation and facilitation cost £1,044
Total cost of workshop £4,172
PC Stefanie Radford (Including: Arranging attendees 
via email, Room booking, Agenda planning, Printing, 
one-to-one meetings in advance(Identified suitable 
attendees from intervention/exampler sites - visited 
them - follow up), Searched online for cardiac and 
stroke contacts)
PC Stefanie Radford: Workshop venue was hosted by 
NHS London at MWB (used Arundel room), cost 
includes refreshments for 16 people.
Unit costs of health and social care 2013
Assumes 2 hours meeting + 2 hours travel time
Assumes top and bottom 20% invited
Assumes two representatives from each trust attend 
plus three additional experts
Educational meetings                       Leader 
Computerised clinical decision support system Educational outreach visits
Reminders Facilitation
Organisational Educational material                      
Financial Audit and feedback                         
QI strategy Electronic guideline
Local opinion Multifaceted
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For the NP case study it is suggested that ‘organisational, educational, opinion leader, educational 
outreach, facilitation’ are the most relevant initiative types. Two studies were identified by a 
systematic reviewer as being of the greatest relevance to the BNP case study, see Table 4.4C. 
Estimates of effect size from the O’Brien et al study were considered the most relevant.21 
Table 4.4C: Studies reporting effectiveness of implementation activities selected from the 
systematic review 
Study  Objective of the 
study  
Results  
Baskerville 2012 Overall effect size of 
practice facilitation 
studies that identified 
evidence-based 
guideline 
implementation 
within primary care 
practices as the 
outcome  
 
Some studies included looked at number of tests. 
Practice facilitation has a moderately robust effect on 
evidence based guideline adoption within primary 
care. Implementation fidelity factors, such as 
tailoring, the number of practices per facilitator, and 
the intensity of the intervention, have important 
resource implications. 
 An overall effect size of 0.56 (95% CI, 0.43-
0.68) favoured practice facilitation (z = 8.76; 
P <.001) 
 publication bias was evident 
 Primary care practices are 2.76 (95% CI, 
2.18-3.43) times more likely to adopt 
evidence-based guidelines through practice 
facilitation.  
O’Brien et al, 
2008
21
  
To assess the effects 
of education 
outreach visits on the 
practice of 
healthcare 
professionals or 
patient outcomes.  
Reports a large number of comparisons between 
education outreach visits, alone or in combination 
with other interventions, and no intervention on a 
variety of outcomes. Relevant results are those 
referring to the effect of the interventions on 
prescribing (reported as median adjusted risk 
difference and interquartile range):  
 Effect of multifaceted interventions: 8.8% 
(2.9%-12.7%)  
 Effect of education outreach visits alone: 
5.0% (3.0-6.23%).  
 
 
 
 
4.4.5 Estimates of effectiveness of implementation initiative used in the model 
It was not possible to estimate the effectiveness of the London BNP initiative as data was only 
available from two trusts. Hence, estimates of effect size from the O’Brien et al study were used as 
these were considered the most relevant.21 In the base case analysis an effect size of 5% was used 
and a scenario analysis applied an effect size of 9%. Figure 4.4 below shows the predicted diffusion 
of utilisation with and without the implementation intervention. 
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Figure 4.4: Predicted diffusion of utilisation with and without an implementation intervention
 
 
4.5 Value of implementation activity. What is the value of specific implementation 
activities given their costs? 
The value of the implementation activity is inversely related to its costs. The costs of the activity may 
include not only the development and roll out of the implementation activity itself, but also any 
costs related to service reconfiguration. It does not include the costs of the intervention and other 
costs included in the appraisal (e.g. costs of monitoring). The costs of an implementation initiative 
will be based on the estimated cost of the LSDN project, see Table 4.5. 
Table 4.5: Costs of implementation activity used in the base case 
 
4.6 Multi-period analysis 
A multi-period analysis was undertaken for 10 years from 2012. The multi-period analysis was 
started in 2012 as this was the time point for which utilisation data was available. Future costs and 
QALYs accrued were discounted at a rate of 3.5% in line with the NICE methods guide. This analysis 
assumes that the increase in utilisation of the intervention does not change the population size. 
However the population presenting with suspected HF was assumed to increase at a rate of 4.2% per 
annum, based on Hospital Episode Statistics data on the number of finished consultant episodes 
with a primary diagnosis of heart failure.1 The total value of the implementation activity over the 10 
year period was calculated. 
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4.7 Scenario analyses 
The following scenario analyses were undertaken to explore the impact of key uncertainties on 
model results: 
 Population size: annual rate of suspected HF 0.27% (population of 150,000) 
 Current utilisation of BNP testing 63% 
 Efficacy of the implementation intervention 9% increase. 
In addition a generalizability analysis was undertaken. This indicates the minimum increase in 
utilisation for a given cost of an implementation activity that is still of value to the NHS and, 
conversely, the maximum cost for a given increase in utilisation for a threshold of £20,000 and 
£30,000 per QALY gained.  
 
5 Results 
5.1 Net benefit. Is the technology of value to the NHS? 
NICE has recommended that testing for NPs in patients with suspected heart failure without 
previous MI can accelerate diagnosis of heart failure and also avoid unnecessary echocardiography.3 
The value of NP testing in patients without previous MI was estimated at £1,524 or 0.076 QALYs for 
a threshold of £20,000 per QALY gained and £2,288 or 0.076 QALYs for a threshold of £30,000 per 
QALY gained. 
 
5.2 Current value. What is the value of the technology given current utilisation and 
population size? 
Table 5.2 shows the current value of NP testing for the suspected HF population. The current value 
represents the benefit of NP testing to the NHS given the patient population currently receiving 
testing. The current value to the NHS is approximately £164 million or 8,230 QALYs for a threshold of 
£20,000 per QALY gained. 
 
 
 
Table 5.2: Static population analysis with base case assumptions 
22 
 
 
5.3 Expected value of perfect implementation. What is the value of increasing 
utilisation so all eligible patients receive the test? 
Table 5.2 presents the expected value of perfect implementation of NP testing for the overall 
population with suspected HF. The expected value of perfect implementation represents the 
maximum amount that the NHS should invest in implementation activities whilst still accruing a non-
negative value from NP testing. It corresponds to the value of NP testing in the eligible population 
currently not receiving testing. The expected value of perfect implementation is approximately 
£155million or 7,774 QALYs for the suspected HF population in England and Wales for a threshold of 
£20,000 per QALY gained.  
5.4 Expected value of actual implementation. What is the value of increasing 
utilisation from current to achievable? 
Table 5.2 shows the expected value of implementation assuming that the implementation activity 
increases utilisation by 5% (from 51% to 56%) for the base-case. The 5% increase in utilisation 
corresponds to the average effectiveness of educational outreach activities as reported in the 
literature.21 The expected value of actual implementation is much smaller than the expected value of 
perfect implementation. For the overall population in England and Wales, the NHS could invest up to 
£16million for an activity that increases utilisation by 5% at a threshold of £20,000 (approximately 
£3million for a one percent increase in utilisation). 
5.5 Value of implementation activity. What is the value of specific implementation 
activities given their costs? 
Table 5.2 shows the value of an implementation activity costing an average of £4,172 per 25 
providers (£28,187 for the whole England and Wales). As the implementation activity has a relatively 
low cost the value of the implementation activity is similar to the expected value of actual 
implementation providing additional value to the NHS at £16million or 799 QALYs for England and 
Wales at a threshold of £20,000 per QALY.  
NMB NHB NMB NHB
Net Benefit to the NHS £1,524 0.076              £2,288 0.076              
Current value of technology given current utilisation and 
population size. Population= 210000, current utilisation= 4.43
£164,594,517 8,230              £247,101,322 8,237              
Expected Value of Perfect Implementation. Value of 
increasing utilisation from current to desirable maximum. 
Current utilisation=4.43, Desirable maximum=8.62
£155,486,060 7,774              £233,427,041 7,781              
Expected Value of Actual Implementation. Value of increasing 
utilisation from current to achievable. Current 
utilisation=4.43, Achievable utilisation with intervention=4.86
£16,004,029 800                  £24,026,418 801                  
Value of the implementation activity. Expected value of 
actual implementation minus cost of intervention (£28,187)
£15,975,842 799                  £23,998,232 800                  
Static population analysis
WTP=£20000 WTP=£30000
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5.6 Multi-period analysis 
The multi-period analysis demonstrates how the value of the implementation activity accrues over a 
10 year period, see Table 5.6. The total value of the implementation activity over 10 years is 
£76million. 
Table 5.6: Multi-period analysis with base case assumptions 
 
 
5.7 Scenario analyses 
A scenario analysis around the size of the eligible population was undertaken to explore the impact 
of the uncertainty in the size of the HF population. In this analysis the annual rate of suspected HF 
was assumed to be 0.27% (equivalent to an eligible population of 150,000). The results of this 
analysis are presented in Table 5.7A. 
Multi-period analysis:  Predictions for 10 years, including discounting, WTP=£20000
Year
Population 
presenting 
with 
suspected HF*
Predicted 
utilisation 
without 
intervention
Predicted 
utilisation 
with 
intervention
Perfect 
Implementation
Current 
value
Expected Value 
of Actual 
Implementation
Expected Value 
of Perfect 
Implementation
Value of 
Implementation 
Activity
2012 210,000             51% 56% 100% £163.2 £179.2 £320.1 £16.0
2013 218,820             72% 77% 100% £230.9 £247.0 £322.2 £16.1
2014 228,010             86% 91% 100% £279.0 £295.2 £324.4 £16.2
2015 237,587             94% 99% 100% £306.1 £322.4 £326.6 £16.3
2016 247,566             97% 100% 100% £320.0 £328.8 £328.8 £8.8
2017 257,963             99% 100% 100% £327.3 £331.1 £331.1 £3.7
2018 268,798             100% 100% 100% £331.7 £333.3 £333.3 £1.6
2019 280,087             100% 100% 100% £334.9 £335.5 £335.5 £0.6
2020 291,851             100% 100% 100% £337.5 £337.8 £337.8 £0.3
2021 304,109             100% 100% 100% £340.0 £340.1 £340.1 £0.1
TOTAL £2,971 £3,051 £3,300 £80
Al l  costs  are presented in £mi l l ions , a l l  costs  are discounted at annual  rate of 3.5% from 2013 onwards
*Assumes  HF incidence increas ing by 4.2% per annum
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Table 5.7A: Scenario analysis – size of eligible population
 
 
A scenario analysis around the current utilisation of BNP testing was undertaken to explore the 
impact of uncertainty in the maximum optimal utilisation rate for NP testing. In this analysis a 
current utilisation rate of 63% was assumed which is derived from a maximum optimum utilisation 
rate of 7.1 BNP tests per 1,000 GP population. The results of this analysis are presented in Table 
5.7B. 
Table 5.7B: Scenario analysis – maximum optimum utilisation rate 
 
NMB NHB NMB NHB
Net Benefit to the NHS £1,524 0.076              £2,288 0.076              
Current value of technology given current utilisation and 
population size. Population= 150000, current utilisation= 4.43
£117,567,512 5,878              £176,500,945 5,883              
Expected Value of Perfect Implementation. Value of 
increasing utilisation from current to desirable maximum. 
Current utilisation=4.43, Desirable maximum=8.62
£111,061,471 5,553              £166,733,600 5,558              
Expected Value of Actual Implementation. Value of increasing 
utilisation from current to achievable. Current 
utilisation=4.43, Achievable utilisation with intervention=4.86
£11,431,449 572                  £17,161,727 572                  
Value of the implementation activity. Expected value of 
actual implementation minus cost of intervention (£28,187)
£11,403,263 570                  £17,133,541 571                  
Static population analysis
WTP=£20000 WTP=£30000
NMB NHB NMB NHB
Net Benefit to the NHS £1,524 0.076              £2,288 0.076              
Current value of technology given current utilisation and 
population size. Population= 210000, current utilisation= 4.43 
(63%)
£200,396,149 10,020            £300,849,350 10,028            
Expected Value of Perfect Implementation. Value of 
increasing utilisation from current to desirable maximum. 
Current utilisation=4.43, Desirable maximum=7.08 (100%)
£119,684,427 5,984              £179,679,013 5,989              
Expected Value of Actual Implementation. Value of increasing 
utilisation from current to achievable. Current 
utilisation=4.43, Achievable utilisation with intervention=4.79 
(68%)
£16,004,029 800                  £24,026,418 801                  
Value of the implementation activity. Expected value of 
actual implementation minus cost of intervention (£28,187)
£15,975,842 799                  £23,998,232 800                  
Static population analysis
WTP=£20000 WTP=£30000
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A scenario analysis around the current utilisation of BNP testing was undertaken to explore the 
impact of uncertainty in the efficacy of implementation intervention. In this analysis an increase in 
utilisation of 9% as a result of the intervention was assumed. The results of this analysis are 
presented in Table 5.7C. 
Table 5.7C: Scenario analysis – efficacy of the implementation intervention 
  
Generalizability analysis 
This indicates the minimum increase in utilisation for a given cost of an implementation activity that 
is still of value to the NHS and, conversely, the maximum cost for a given increase in utilisation for a 
threshold of £20,000 and £30,000 per QALY gained. The generalizability analysis provides indicative 
estimates of costs and effectiveness which could be applied to a broader range of implementation 
activities. The results of the generalizability analysis are presented in Table 5.7D and Figure 5.7. For 
an initiative resulting in a 5% absolute increase in utilisation there would be value to the NHS if the 
cost of the initiative was less that £16million (for a WTP threshold of £20,000). 
Table 5.7D: Generalisability analysis 
 
 
NMB NHB NMB NHB
Net Benefit to the NHS £1,524 0.076              £2,288 0.076              
Current value of technology given current utilisation and 
population size. Population= 210000, current utilisation= 4.43 
(51%)
£164,594,517 8,230              £247,101,322 8,237              
Expected Value of Perfect Implementation. Value of 
increasing utilisation from current to desirable maximum. 
Current utilisation=4.43, Desirable maximum=8.62 (100%)
£155,486,060 7,774              £233,427,041 7,781              
Expected Value of Actual Implementation. Value of increasing 
utilisation from current to achievable. Current 
utilisation=4.43, Achievable utilisation with intervention=5.19 
(60%)
£28,167,091 1,408              £42,286,496 1,410              
Value of the implementation activity. Expected value of 
actual implementation minus cost of intervention (£28,187)
£28,138,904 1,407              £42,258,309 1,409              
Static population analysis
WTP=£20000 WTP=£30000
Threshold below which the implementation initiative is of value to the NHS
WTP=£20K WTP=£30K
0% £0 £0
5% £16 £24
10% £32 £48
15% £48 £72
20% £64 £96
25% £80 £120
Cost of the implementation initiative in 
£millions
Effectiveness of initiative in 
terms of absolute increase in 
utilisation
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Figure 5.7: Generalisability analysis 
 
 
6 Discussion  
6.1 Conclusions 
The value of the implementation activity depends on its costs and effectiveness in increasing 
utilisation. In this case study, there appears to be value in additional implementation efforts directed 
towards encouraging the utilisation of NP testing for persons with suspected HF without previous 
MI. At a threshold of £20,000 per QALY gained, additional investment in an activity that increases 
utilisation by 5% (absolute increase in utilisation rates) would generate an additional 799 QALYs (£16 
million in terms of monetary equivalent) across England and Wales compared to the use of these 
resources in other (health generating) NHS activities.  Scenario analyses demonstrated that value to 
the NHS was sensitive to uncertain model inputs such as the size of the eligible population and the 
efficacy of the implementation intervention. 
6.2 Strengths 
These analyses demonstrate a practical application of the implementation frame work to a case 
study. They estimate the added value to the NHS of investing in activities that increase utilisation of 
recommended interventions. This framework can help the NHS in general and commissioners in 
particular in quantifying the value of investing resources in increasing utilisation in a manner 
consistent with the value assessment of new interventions conducted by NICE. Scenario analysis 
shows how changes in model parameters can affect the predicted value of implementation. This 
case study provides a useful demonstration of the practical challenges faced in populating such a 
model.  
6.3 Limitations 
The main limitations of the analysis are a lack of evidence on: cost effectiveness, effectiveness of 
implementation intervention, utilisation, and population size. 
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The lack of evidence on cost effectiveness was a key limitation. The clinical guidelines did not include 
an economic evaluation in relation to the use of NP testing for HF diagnosis. The HTA on which the 
clinical guideline development was based did include an economic model, however the diagnostic 
strategy recommended in the guidelines was not modelled. In addition the most relevant 
comparator (ECG) was not included within the economic evaluation; hence, estimates of 
incremental costs and QALYs are likely to be considerably overestimated by using the ‘do nothing’ 
comparator. 
There was a lack of evidence on utilisation rates of NP testing. Although data on current rates of NP 
testing were available, obtaining an estimate of maximum optimal rates was very difficult. There was 
a disparity between estimated optimal rates based on the suspected heart failure population and 
rates observed in the diagnostics Atlas data set. Robust data on NP testing rates were only available 
for one time point so estimated diffusion curves were subject to considerable uncertainty. 
There was a lack of evidence on the effectiveness of implementation initiatives. There was detailed 
evidence describing several initiatives specifically designed to increase utilisation of NP testing, 
however evidence of their efficacy was very limited. The literature on the effectiveness of more 
general implementation initiatives is of limited quality and difficult to generalise to this specific case 
study. 
There was considerable uncertainty surrounding the evidence on population size. The differences in 
estimates of population size from different published data sources highlights the importance of 
validating data sources with clinical experts. 
 
6.4 Key uncertainties and areas for future research 
The key areas of uncertainty relates to a lack of evidence on cost effectiveness, population size and 
utilisation. These areas are detailed in the limitations section above and are key areas for future 
research. 
Multi-period analysis requires an understanding of how the patient population will change over 
time. Predictions of changes in utilisation rates over time with and without an intervention are also 
required. Diffusion curve methodology can be used to predict how utilisation will change over time 
in the future but the generation of a diffusion curve is associated with considerable data 
requirements. 
Parameter uncertainty could be quantified using probabilistic sensitivity analyses; however, this 
approach requires data on the variability of parameter inputs. Extending the analysis to incorporate 
this uncertainty in a probabilistic model of the value of implementation is an area for future 
research. 
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